Skip to main content
SpringerLink
Log in

No safety concerns for HepB-CpG versus HepB-alum

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ackerson B, et al. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine : 10 Jun 2023. Available from: URL: http://doi.org/10.1016/j.vaccine.2023.06.004

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

No safety concerns for HepB-CpG versus HepB-alum. Reactions Weekly 1963, 9 (2023). https://doi.org/10.1007/s40278-023-42065-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-42065-x

Search

Navigation